采用ＣＡＰ－ＣＥ方案治疗６８例晚期非小细胞肺癌（ＮＳＣＬＣ），全部病例均经细胞学或病理证实，均为初治病例，有明确可评价的临床和ｘ线观察指标。治疗后其近期疗效为：完全缓解２例，部份缓解２７例，稳定３０例，总有效率为４３．９％。ＣＡＰ－ＣＥ方案治疗的主要毒性为消化道反应和骨髓抑制，均可耐受，无一例因毒副反应而停止化疗 The CAP-CE protocol was used to treat 68 patients with advanced non-small-cell lung cancer (NSCLC). All cases were confirmed by cytology or pathology. All cases were initially treated, and there were clearly assessable clinical and x-ray findings. After treatment, its short-term efficacy was as follows: complete remission in 2 cases, partial remission in 27 cases, and stabilization in 30 cases. The total effective rate was 43.9%. The main toxicities of the CAP-CE regimen were gastrointestinal reactions and myelosuppression, both of which were tolerable, and none of them stopped due to toxic and side effects.